Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 20/20 | 0.39 |
| ▸ | MERTK | Q12866 | 18/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 16/20 | 0.39 |
| ▸ | MET | P08581 | 14/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777680 | 1.00 | AXL (0.39) | AXLMERTKTYRO3MET | |
| SCHEMBL30208908 | 1.00 | AXL (0.39) | AXLMERTKTYRO3MET | |
| SCHEMBL21777681 | 1.00 | AXL (0.39) | AXLMERTKTYRO3MET | |
| SCHEMBL30208967 | 1.00 | AXL (0.39) | AXLMERTKTYRO3MET | |
| SCHEMBL21797895 | 0.93 | AXL (0.40) | AXLMERTKTYRO3MET | |
| SCHEMBL30208927 | 0.93 | AXL (0.40) | AXLMERTKTYRO3MET | |
| SCHEMBL21785591 | 0.93 | AXL (0.40) | AXLMERTKTYRO3MET | |
| SCHEMBL21777705 | 0.92 | AXL (0.38) | AXLMERTKTYRO3MET | |
| SCHEMBL21786090 | 0.92 | AXL (0.38) | AXLMERTKTYRO3MET | |
| SCHEMBL21777704 | 0.92 | AXL (0.38) | AXLMERTKTYRO3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20200079770-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. | 2020-03-12 | — | — | US | disclosed |
| WO-2020047184-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079770-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | AXL 14/4885MERTK 2/4885TYRO3 7/4885 |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | RET, MERTK, MET | AXL 20/4885MERTK 2/4885TYRO3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.